London Genetics Conference Proceedings Published in Drug Discovery Today

LONDON, May 12, 2010 - London Genetics Limited, an expert in the use of
pharmacogenetics in clinical drug discovery and development, is pleased to
announce that the importance of this approach is being highlighted with the
publication of its inaugural conference [1] proceedings in the May 2010 issue
of Drug Discovery Today. The conference, 'Harnessing Genetic Knowledge To
Improve Clinical Development and Patient Care'[2], brought together pharma
and biotech companies, academia and regulatory bodies to discuss the value
that pharmacogenetics can bring to drug development.

Recognising that pharmacogenetics is a key part of the mission
to get the right drug to the right patient at the right dose, delegates
discussed how to integrate it more fully into drug development. Issues
debated ranged from the role of pharmacogenetics in cost-effectiveness
studies, possible changes in the way clinical trials are performed, and the
need for sophisticated bioinformatics to capture and analyse data. One of the
conclusions reached was that early collaboration between academia, industry,
the regulatory authorities, and those that foot the healthcare bill was
pivotal for capturing the maximum potential from pharmacogenetics.

Dominique Kleyn, CEO of London Genetics, said 'Drug Discovery
Today is recognised as being at the cutting edge of new developments
underlying R&D in the pharma and biotech industry. Publication of our article
provides a strong validation of the potential of pharmacogenetics, and the
importance of the issues raised at London Genetics' inaugural conference. We
look forward to discussing progress in the field at our second
pharmacogenetics conference, to be held in November 2010 in Windsor, UK.'

To access the Drug Discovery Today article, please go to
bit.ly/bVrRpv, where it is available as a download.

[1] Editorial: Pharmacogenetics - pivotal to the future of the
biopharmaceutical industry. Drug Discovery Today pp 325-327, Volume 15,
Numbers 9/10, May 2010.

[2] 1st Annual London Genetics Pharmacogenetics Conference 'Harnessing
Genetic Knowledge to Improve Clinical Development and Patient Care', 23rd
-24th September 2009, Tylney Hall, Hampshire, UK.

Notes to Editors:

About London Genetics

London Genetics Limited, a not-for-profit company, is an
expert in the use of pharmacogenetics in clinical drug discovery and
development. Established in 2007 with funding from the London Development
Agency, its seven founding partners are leading London academic and medical
institutions with clinical and genetic expertise and significant patient
resources. The company provides pharmaceutical and biotechnology companies
with access to this expertise and resource, as well as providing strategic
advice on the application of pharmacogenetics for successful drug
development. LGL has broad therapeutic expertise with a focus on
cardiovascular disease and drug side-effects of a cardiovascular nature.
Recent agreements developed by London Genetics include a collaboration
between the International Serious Adverse Events Consortium, St George's
University of London and the Drug Safety Research Unit at Southampton, UK.
The parties are working on genetic markers for drug-induced cardiac
arrhythmia. LGL is based in central London and has ISO 9001 accreditation.
For further information, please go to www.londongenetics.com

About pharmacogenetics

Genetic differences between individuals mean that drug
response rates are often variable across a population, and this has
significant implications for healthcare cost effectiveness. Pharmocogenetics,
the study of the clinical consequences of genetic differences in the way
people metabolise and respond to drugs, is expected to generate better
understanding of how drugs work in the body, and therefore give insight into
how to develop more efficacious and safer drugs. It also has implications for
product life cycle management and the revitalisation of drugs which
previously failed in clinical trials. With drug development costs rising and
R&D productivity falling, plus increased regulator focus on safety and
cost-effectiveness, pharmacogenetics is expected to become increasingly
important in drug development. The FDA and the EMA have recognised this in
their Critical Path Initiative and Road Map respectively.

    For further information please contact:
    London Genetics Ltd
    Dominique Kleyn, CEO +44(0)207-594-1838
    Emma Palmer Foster, Strategic Communications Consultant
    +44(0)7880-787185
    communications@londongenetics.com

For further information please contact: London Genetics Ltd, Dominique Kleyn, CEO +44(0)207-594-1838, Emma Palmer Foster, Strategic Communications Consultant, +44(0)7880-787185, communications at londongenetics.com